Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Period

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14,142 result(s) found for: Period. Displaying page 1 of 708.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-000239-29 Sponsor Protocol Number: PEC19156 Start Date*: 2021-07-09
    Sponsor Name:BIOGAIA PHARMA
    Full Title: A randomized placebo-controlled study to assess safety and preliminary efficacy of BGP345A in patients with constipation due to the use of opioid-based medications for the management of chronic non...
    Medical condition: Opioid induced constipation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004518-24 Sponsor Protocol Number: I4V-MC-JAHV Start Date*: 2019-04-23
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Juvenile Idiopathic Arthritis (JIA)
    Medical condition: Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) DE (Completed) AT (Completed) ES (Ongoing) PL (Completed) FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000717-20 Sponsor Protocol Number: SP0967 Start Date*: 2015-06-03
    Sponsor Name:UCB Biosciences Inc.
    Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY ≥1 MONTH TO <4...
    Medical condition: Epilepsy with partial onset seizures
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) CZ (Completed) LT (Completed) IT (Completed) DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) PL (Completed) RO (Completed) GR (Completed) BG (Completed) HR (Completed) SK (Completed) BE (Completed) PT (Completed) DK (Prematurely Ended) FI (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-003179-33 Sponsor Protocol Number: BV-2021/06 Start Date*: 2021-11-29
    Sponsor Name:OM Pharma SA
    Full Title: A Randomised, Double-Blind, Placebo-controlled, 32-week, Phase IIa trial to investigate the efficacy of OM-85 versus matched placebo in reducing disease severity in children aged 3 to 24 months wit...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004952-30 Sponsor Protocol Number: E2080-J081-304 Start Date*: 2017-02-13
    Sponsor Name:Eisai Co, Ltd.
    Full Title: A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients
    Medical condition: Lennox-Gastaut Syndrome (LSG)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004996-38 Sponsor Protocol Number: SP0969 Start Date*: 2013-11-25
    Sponsor Name:UCB BIOSCIENCES, Inc.
    Full Title: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY ≥4 YEARS TO <1...
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) BE (Completed) IT (Completed) LV (Completed) EE (Completed) CZ (Completed) ES (Completed) PL (Completed) GB (Completed) LT (Completed) BG (Completed) RO (Completed) Outside EU/EEA SI (Completed) HR (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004549-23 Sponsor Protocol Number: TV48125-CNS-30049 Start Date*: 2016-11-24
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for...
    Medical condition: Chronic Migraine
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10066636 Chronic migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed) FI (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000630-57 Sponsor Protocol Number: 20150308 Start Date*: 2017-08-08
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention.
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10058734 Migraine prophylaxis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed) SE (Completed) FI (Completed) DE (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003622-41 Sponsor Protocol Number: EP0008 Start Date*: 2014-09-22
    Sponsor Name:UCB Pharma SA
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontr...
    Medical condition: Partial Onset Seizures
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005174-11 Sponsor Protocol Number: U1111-1166-6923 Start Date*: 2015-10-01
    Sponsor Name:Uppsala University Hospital
    Full Title: A randomized, double-blinded placebo-controlled, paralleled designed, investigator sponsored study of the effect of the GLP-1 receptor agonist liraglutide on beta-cell function in C-peptide positiv...
    Medical condition: Beta-cell function in C-peptide positive type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000766-12 Sponsor Protocol Number: SCO/BIA-2093-301 Start Date*: 2005-03-21
    Sponsor Name:BIAL Portela & Companhia, S.A.
    Full Title: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial
    Medical condition: About 40% of the patients suffering from epilepsy are not satisfactorily controlled and 25% suffer from significant adverse events. This lack of seizure control means that combination therapy is of...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001560-11 Sponsor Protocol Number: CQAW039A2315 Start Date*: 2017-03-21
    Sponsor Name:Novartis Pharma AG
    Full Title: A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with un...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) DE (Completed) LV (Prematurely Ended) EE (Completed) HU (Completed) BE (Completed) GR (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) CZ (Completed) LT (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) FI (Prematurely Ended) BG (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-005338-74 Sponsor Protocol Number: CLFG316X2201 Start Date*: 2015-06-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label proof of concept study to assess the efficacy, safety and pharmacokinetics of LFG316, an anti-C5 monoclonal antibody in patients with paroxysmal nocturnal hemoglobinuria (PNH)
    Medical condition: Paroxysmal nocturnal hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000848-95 Sponsor Protocol Number: 020119 Start Date*: 2019-07-29
    Sponsor Name:Dansk Hovedpine Center, Neurologisk Klinik, Rigshospitalet - Glostrup
    Full Title: A Placebo-Controlled, Double-Blind, Randomized, Proof-of-Concept Study to Evaluate the Efficacy and Tolerability of Erenumab in Patients with Trigeminal Neuralgia
    Medical condition: Trigeminal neuralgia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10044652 Trigeminal neuralgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001203-21 Sponsor Protocol Number: EP0083 Start Date*: 2022-11-18
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Subjects (>=16 to 80 Years of Age) With Partial S...
    Medical condition: Epilepsy (partial seizures with or without secondary generalization)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000518-13 Sponsor Protocol Number: 2011-398 Start Date*: 2012-06-21
    Sponsor Name:Prof. Per Soelberg Sørensen
    Full Title: Immunomodulating and neuroprotective properties of autologous multipotent mesenchymal stem cells in patients with multiple sclerosis - A randomised placebo-controlled double-blinded phase II study
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-005173-27 Sponsor Protocol Number: 0858A4-318-WW Start Date*: 2005-10-21
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF A COMBINATION OF LEVONORGESTREL AND ETHINYL ESTRADIOL IN A CONTINUOUS DAILY REGIMEN IN SUBJECTS WITH PREMENSTRUAL DYSPHORIC DISO...
    Medical condition: Premenstrual dysphoric disorder (PMDD) affects 3% to 5% of menstruating women. PMDD is defined by markedly depressed mood, anxiety, and/or affective lability during the last week of the late lutea...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) FI (Completed) SE (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004335-39 Sponsor Protocol Number: N01223 Start Date*: 2015-02-16
    Sponsor Name:UCB Japan Co. Ltd.
    Full Title: An Open Label, Single-Arm, Multi-Center Study on the Efficacy, Safety and Pharmacokinetics of Levetiracetam in Pediatric Patients (4 to 16 Years) With Partial Seizures Despite Treatment With 1 or 2...
    Medical condition: Epilepsy Partial Seizures
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003349-15 Sponsor Protocol Number: ARPH-CL-03 Start Date*: 2006-02-07
    Sponsor Name:Ariston Pharmaceuticals, Inc
    Full Title: Intranasal Hydroxocobalamin (AST-726) Treatment for Prohylaxis of Migraine: a Placebo-Controlled, Clinical Study
    Medical condition: Migraine headache with and without aura
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058734 Migraine prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004416-78 Sponsor Protocol Number: MRZ 60201-0520/1 Start Date*: 2006-08-30
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, randomized, double-blind, placebo-controlled, multicenter trial with an open-label extension period to investigate the efficacy and safety of NT 201, free of complexing proteins, in ...
    Medical condition: Treatment of glabellar frown lines
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 19:20:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA